New antifungal agents

Dermatologic Clinics

Volumn 21, Issue 3, 2003, Pages 565-576

  Gupta, Aditya K ^a,b,c   Tomas, Elizabeth ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BILIRUBIN; CASPOFUNGIN; CLOTRIMAZOLE; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; PNEUMOCANDIN DERIVATIVE; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; TERBINAFINE; VORICONAZOLE;

ABDOMINAL PAIN; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; BLOOD TOXICITY; CANDIDA; CHEILITIS; CHILL; CLINICAL TRIAL; COLOR VISION DEFECT; CROSS RESISTANCE; CRYPTOCOCCUS NEOFORMANS; DERMATOMYCOSIS; DIARRHEA; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG RESISTANCE; DRUG SAFETY; FEVER; FLUSHING; GRANULOMATOSIS; HEADACHE; HUMAN; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; ONYCHOMYCOSIS; PHLEBITIS; PHOTOPHOBIA; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SIDE EFFECT; SPECIES DIFFERENCE; STANDARDIZATION; VISUAL DISORDER; VISUAL HALLUCINATION; VISUAL IMPAIRMENT;

EID: 0043015832     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(03)00024-X     Document Type: Review

References (113)

1. Hossain MA, Ghannoum MA. New investigational antifungal agents for treating invasive fungal infections. Exp Opin Invest Drugs 2000;9:1797-813.
2. Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001; 7(suppl 2):8-24.
3. Singh N. Changing spectrum of invasive candidiasis and its therapeutic implications. Clin Microbiol Infect 2001;7(suppl 2):1-7.
4. Slavin MA, Australian Mycology Interest Group. The epidemiology of candidaemia and mould infections in Australia. J Antimicrob Chemother 2002; 49(suppl S1):3-6.
5. Cuenca-Estrella M, Rodriguez-Tudela JL. Present status of the detection of antifungal resistance: the perspective from both sides of the ocean. Clin Microbiol Infect 2001;7(suppl 2):46-53.
6. Lozano-Chiu M, Arkian S, Paetznick VL, Anaissie EJ, Rex JH. Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility. J Clin Microbiol 1999;37:2755-9.
7. Perea S, Fothergill AW, Sutton DA, Rinaldi MG. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method. J Clin Microbiol 2001;39:385-8.
8. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2002;150:101-15.
9. Gupta A, Sauder DN, Shear NH. Antifungal agents: an overview. Part I. J Am Acad Dermatol 1994;30: 677-98.
10. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-93.
11. Arikan S, Rex JH. Lipid-based antifungal agents: current status. Curr Pharm Des 2001;7:393-415.
12. Brajtburg J, Bolard J. Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev 1996; 9:512-31.
13. Hann IM, Prentice HG. Lipid-based amphotericin B: a review of the last 10 years of use. Int J Antimicrob Agents 2001;17:161-9.
14. Rapp RP, Gubbins PO, Evans ME. Amphotericin B lipid complex. Ann Pharmacother 1997;31:1174-86.
15. Robinson RF, Nahata MC. A comparative review of conventional and lipid formulations of amphotericin B. J Clin Pharm Ther 1999;24:249-57.
16. Cagnoni PJ. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother 2002;49(suppl S1):81-6.
17. Hay RJ. Treatment of dermatomycoses and onychomycoses: state of the art. Clin Exp Dermatol 1992; 17(suppl 1):2-5.
18. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002;46:1773-80.
19. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Hematol 1997;98:711-8.
20. Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002; 137:105-9.
21. Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001;45: 3487-96.
22. Chen SCA, Australasian Society for Infectious Diseases Mycoses Interest Group. Cryptococcosis in Australasia and the treatment of cryptococcal and other fungal infections with liposomal amphotericin B. J Antimicrob Chemother 2002;49(suppl S1):57-61.
23. Chopra R. AmBisome in the treatment of fungal infections: the UK experience. J Antimicrob Chemother 2002;49(suppl S1):43-7.
24. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002;49(suppl S1):37-41.
25. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002; 49(suppl S1):31-6.
26. Lequaglie C. Liposomal amphotericin B (AmBisome): efficacy and safety of low-dose therapy in pulmonary fungal infections. J Antimicrob Chemother 2002; 49(suppl S1):49-50.
27. Ringdén O. Ten years' experience with liposomal amphotericin B in transplant recipients at Huddinge University Hospital. J Antimicrob Chemother 2002; 49(suppl S1):51-5.
28. Tollemar J, Klingspor L, Ringdén O. Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children. Clin Microbiol Infect 2001;7(suppl 2):68-79.
29. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999;12:40-79.
30. Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann Pharmacother 2000;34: 1032-43.
31. Pfizer. VFEND (voriconazole) proposed US package insert. Available at: http://www.pfizercom/download/ uspi_vfend.pdf. Accessed June 7, 2003.
32. Barry AL, Brown SD. In vitro studies of two triazole antifungal agents (voriconazole [UK-109, 496] and fluconazole) against Candida species. Antimicrob Agents Chemother 1996;40:1948-9.
33. Belanger P, Nast CC, Fratti R, Sanati H, Ghannoum M. Voriconazole (UK-109, 496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997;41:1840-2.
34. Kauffman CA, Zarins LT. In vitro activity of voriconazole against Candida species. Diagn Microbiol Infect Dis 1998;31:297-300.
35. Kronvall G, Karlsson I. Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation. J Clin Microbiol 2001; 39:1422-8.
36. Laverdiere M, Hoban D, Restieri C, Habel F. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 2002;50:119-23.
37. Marco F, Pfaller MA, Messer S, Jones RN. In vitro activities of voriconazole (UK-109, 496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother 1998; 42:161-3.
38. Nguyen MH, Yu CY. Voriconazole against fluconazole-susceptible and -resistant Candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. J Antimicrob Chemother 1998;42: 253-6.
39. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001;39:3254-9.
40. Pfaller MA, Messer SA, Gee S, Joly S, Pujol C, Sullivan DJ, et al. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinochandin antifungal agents. J Clin Microbiol 1999;37:870-2.
41. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, et al. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother 1998;42:3242-4.
42. Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997;41:575-7.
43. Brummer E, Kamei K, Miyaji M. Anticryptococcal activity of voriconazole against Cryptococcus neoformans var. gatti vs var. neoformans: comparison with fluconazole and effect of human serum. Mycopathologia 1998;142:3-7.
44. Nguyen MH, Yu CY. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cyrptococcus neoformans isolates. Antimicrob Agents Chemother 1998;42: 471-2.
45. Pfaller MA, Zhang J, Messer SA, Brandt ME, Hajjeh RA, Jessup CJ, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother 1999;43:169-71.
46. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001;45:2151-3.
47. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002;46:1144-6.
48. Abraham OC, Manavathu EK, Cutright JL, Chandrasekar PH. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Mycology 1999;33:7-11.
49. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. Antimicrob Agents Chemother 2002;46:1032-7.
50. Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with head-to-head comparison to voriconazole. J Clin Microbiol 1999;37:2343-5.
51. Verweij PE, Te Dorsthorst DT, Rijs AJ, De Vries-Hospers HG, Meis JF. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J Clin Microbiol 2002;40: 2648-50.
52. Verweij PE, Mensink M, Rijs AJ, Donnelly JP, Meis JF, Denning DW. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother 1998;42:389-92.
53. Wildfeuer A, Siedl HP, Paule I, Haberreiter A. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses 1998;41:309-19.
54. Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother 2000;44:1734-6.
55. Fernández-Torres B, Carrillo AJ, Martín E, Del Palacio A, Moore MK, Valverde A, et al. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob Agents Chemother 2001;45:2524-8.
56. Rex JH, Nelson PW, Paetznick VL, Lozano-Chiu M, Espinel-Ingroff A, Anaissie EJ. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 1998;42:129-34.
57. Rodriguez-Tudela JL, Cuenca-Estrella M, Diaz-Guerra TM, Mellado E. Standardization of antifungal susceptibility variables for a semiautomated methodology. J Clin Microbiol 2001;39:2513-7.
58. Chandrasekar PH, Cutright J, Manavathu E. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. J Antimicrob Chemother 2000;45:673-6.
59. Murphy M, Bernard EM, Ishimaru T, Armstrong D. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1997;41: 696-8.
60. Neely MN, Ghannoum MA. The exciting future of antifungal therapy. Eur J Clin Microbiol Infect Dis 2000;19:897-914.
61. Kirkpatrick WR, McAtee RK, Fothergill AW, Rinaldi MG, Patterson TF. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 2000;44:2865-8.
62. Walsh TJ, Lustar I, Driscoll T, Dupont B, Roden M, Ghahramani P, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21:240-8.
63. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71.
64. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
65. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34.
66. Kappe R. Antifungal activity of the new azole UK-109,596 (voriconazole). Mycoses 1999;42(suppl 2): 83-6.
67. Ernst EJ. Investigational antifungal agents. Pharmacotherapy 2001;21:165S-74S.
68. Janssen Pharmaceutica. Sporanox (itraconazole) package insert. Titusville, NJ: Janssen Pharmaceuticals; 2001.
69. Moore CB, Walls CM, Denning DW. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother 2000;44: 441-3.
70. Pfizer. Diflucan (fluconazole) package insert. New York: Pfizer; 1998.
71. Diekema DJ, Pfaller MA, Messer SA, Houston A, Hollis RJ, Doern GV, et al. In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY antimicrobial surveillance program in North America and Latin America. Antimicrob Agents Chemother 1999;43:2236-9.
72. Fung-Tomc JC, Huczko E, Minassian B, Bonner DP. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob Agents Chemother 1998;42: 313-8.
73. Hata K, Kimura J, Miki H, Toyosawa T, Nakamura T, Katsu K. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad anfifungal spectrum. Antimicrob Agents Chemother 1996;40: 2237-42.
74. Yamazumi T, Pfaller MA, Messer SA, Houston A, Hollis RJ, Jones RN. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 2000;44:2883-6.
75. Clemons KV, Marinez M, Claderon L, Stevens DA. Efficacy of ravuconazole in treatment of systemic murine histoplasmosis. Antimicrob Agents Chemother 2002;46:922-4.
76. Hata K, Kimura J, Miki H, Toyosawa T, Moriyama M, Katsu K. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis and cryptococcosis. Antimicrob Agents Chemother 1996;40:2243-7.
77. Mikamo H, Yin XH, Hayasaki Y, Satoh M, Tamaya T. Effect of ravuconazole, a new triazole antifungal, in a rat intraabdominal abscess model. Chemotherapy 2001;47:377-80.
78. Petraitis V, Petraitiene R, Lyman CA, Roussillon K, Hemmings M, Armstrong D, et al. The efficacy of ravuconazole in treatment of invasive pulmonary aspergillosis in persistently neutropenic rabbits [abstract J-1611]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: American Society for Microbiology; 2001. p. 390.
79. Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000;44:3381-8.
80. Clemons KV, Stevens DA. Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice. Antimicrob Agents Chemother 2001;45:3433-6.
81. Beale M, Queiroz-Telles F, Banhegyi D, Li N, Pierce PF. Randomized, double-blind study of the safety and antifungal activity of ravuconazole relative to fluconazole in esophageal candidiasis [abstract J-1621]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: American Society for Microbiology; 2001. p. 392.
82. Marino M, Mummaneni V, Norton J, Hadjilambris O, Pierce P. Ravuconazole exposure-response relationship in HIV + patients with oropharyngeal candidiasis [abstract J-1622]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: American Society for Microbiology; 2001. p. 393.
83. Gupta AK, Leonardi C, Stolz R, Conetta B, Pierce P. Evaluation of ravuconazole for the treatment of toenail onychomycosis [abstract P1492]. Ann Dermatol Venereol 2002;129:1S663.
84. Ezzet F, Wexler D, Courtney R, Laughlin M, Lim J, Clement R, et al. The pharmacokinetics of posaconazole in neutropenic oncology patients [abstract A-26]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: American Society for Microbiology; 2001. p. 4.
85. Oakley KL, Moore CB, Denning DW. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother 1997;41: 1124-6.
86. Law D, Moore CD, Denning DW. Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother 1997;41:2310-1.
87. Pfaller MA, Messer S, Jones RN. Activity of a new triazole, Sch56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother 1997;41:233-5.
88. Perfect JR, Cox GM, Dodge RK, Schell WA. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996;40:1910-3.
89. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of Zygomycetes. Antimicrob Agents Chemother 2002;46:1581-2.
90. Barchiesi F, Arzeni D, Camiletti V, Simonetti O, Cellini A, Offidani AM, et al. In vitro activity of posaconazole against clinical isolates of dermatophytes. J Clin Microbiol 2001;39:4208-9.
91. Gupta AK, Kohli Y, Loebenberg D. Comparative antifungal susceptibility testing of Posaconazole (POS) and other antifungal agents against dermatophyte, yeast and non-dermatophyte species. Poster ICAAC; 2002.
92. Oakley KL, Morrissey G, Denning DW. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillusfumigatus. Antimicrob Agents Chemother 1997;41:1504-7.
93. Connolly P, Wheat LJ, Schnizlein-Bick C, Durkin S, Kohler S, Smedema M, et al. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob Agents Chemother 2000;44: 2604-8.
94. Gonzalez G, Tijerina R, Najvar L, Bocanegra R, Rinaldi M, Loebenberg D, et al. Therapeutic efficacy of posaconazole (POSA) in a murine Pseudallescheria boydii infection [abstract J-1615]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: American Society for Microbiology; 2001. p. 391.
95. Najvar LK, Sun QN, Bocanegra R, Loebenberg D, Graybill JR. Posaconazole (POSA) treatment of experimental zygomycosis [abstract J-1616]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: American Society for Microbiology; 2001. p. 391.
96. Ghannoum M, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999;12:501-17.
97. Cuenca-Estrella M, Diaz-Guerra TM, Mellado E, Monzón A, Rodríguez-Tudela JL. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain. Eur J Clin Microbiol Infect Dis 1999;18:432-5.
98. Meletiadis J, Meis JF, Mouton JW, Rodriquez-Tudela JL, Donnelly JP, Verweij PE, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002;46:62-8.
99. Mosquera J, Denning DW. Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2002;46:556-7.
100. Keating GM, Jarvis B. Caspofungin. Drugs 2001;61: 1121-9.
101. Arathoon EG. Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis 2001;14:685-91.
102. Bachmann SP, Patterson TF, Lopez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol 2002; 40:2228-30.
103. Barchiesi F, Schimizzi AM, Fothergill AW, Scalise G, Rinaldi MG. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis 1999;18:302-4.
104. Bartizal K, Gill CJ, Abruzzo GK, Flattery AM, Kong L, Scott PM, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743, 872). Antimicrob Agents Chemother 1997; 41:2326-32.
105. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998;30:251-5.
106. Denning DW. Echinocandins and pneumocandins-a new antifungal class with a novel mode of action. J Antimicrob Chemother 1997;40:611-4.
107. Hoang A. Caspofungin acetate: an antifungal agent. Am J Health Syst Pharm 2001;58:1206-14.
108. Abruzzo GK, Gill C, Flattery AM, Kong L, Leighton C, Smith JG, et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 2000;44:2310-8.
109. Graybill JR, Bocanegra R, Luther M, Fothergill A, Rinaldi MJ. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob Agents Chemother 1997;41:1937-9.
110. Abruzzo GK, Flattery AM, Gill CJ, Kong L, Smith JG, Pikounis VB, et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997; 41:2333-8.
111. Powles MA, Liberator P, Anderson J, Karkhanis Y, Dropinski JF, Bouffard FA, et al. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother 1998;42:1985-9.
112. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002;46: 451-7.
113. Villanueva A, Arathoon EG, Gottuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001;33:1529-35.